Skip to main content

FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.